心臓不全の発生とカテキオラミン無敏感化に対する心臓の無神経化の影響
関連する実験動画
Updated: Nov 2, 2026

05:08
Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
Published on: October 3, 2019
1New England Regional Primate Research Center, Southborough, Mass 01772-9102, USA.
Circulation
|April 15, 1997
まとめ
犬の心臓神経の除去は,心不全の耐性を向上させ,カテキオラミン無敏感化を減少させた. これは,心不全時のカテキオラミン無敏感化の生理学的効果のために,無傷の心室内膜内化が必要であることを示唆しています.
科学分野:
- 心臓病学 心臓病学
- 神経科学は神経科学である.
- 生理学 生理学とは
背景:
- 心不全は,交感神経系の活性化とカテキオラミンの無敏感化によって特徴付けられます.
- 心不全の進行とカテキオラミン無敏感化における心臓神経の役割は不明である.
研究 の 目的:
- 犬における心不全の進行とカテキオラミンの無敏感化に対する選択性心室内膜消去 (Selective Ventricular Denervation,VD) の影響を調査する.
主な方法:
- 静脈疾患の8匹の犬と,無傷の10匹の犬を研究し,血液動力学的測定のための器具を使用した.
- 心不全は急速なペースによって誘発され,VDは神経化学的および生理学的検査によって確認されました.
- 左心室 (LV) 圧力,dP/dt,直径,壁の厚さは,心不全誘導前と後に測定されました.
主要な成果:
- 静脈疾患を持つ犬は,静脈疾患の末期ダイアストリックストレスの増加が少なく,心不全時の静脈疾患のdP/dtの減少が少なく,健全な犬と比較した.
- カテコラミン無感化 (イソプロテレノールとノレアピネフリンに対する無熱反応) は,VD犬では有意に少ない.
- プラズマのノレピネフリン濃度は,心不全中のVDと不傷の犬の間で比較可能でした.
結論:
- 選択的心室脱皮は,犬の心不全の発達に対する耐性を改善しました.
- カテコロアミン無敏感化の生理的発現には,プラズマカテコロアミンの値が上昇した場合でも,無傷な心室内膜内化が必要である.
関連する概念動画
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
